Although IDH1 mutations have been identified in 10% of melanomas in one patient cohort [142], TET and/or IDH gene repression seems to be a more common mechanism for blocking 5-mC to 5-hmC conversion in non-glioma solid tumors rather than TET or IDH mutations, which are found more commonly in gliomas and hematological malignancies. The gene discussed is IDH2; the disease is central nervous system cancer.